Navigation Links
Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Biocodex in France
Date:3/13/2017

TEL AVIV, Israel, March 13, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ('Neurim') announced today that it has entered into a licensing agreement with Biocodex. The agreement grants Biocodex exclusive marketing rights for Neurim's new Rx PedPRM in France.

Neurim's age-appropriate drug is targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep drug approved for children.

Biocodex promotes Circadin®, prolonged-release melatonin 2mg, indicated to treat primary insomnia in the elderly, since 2013 in France. "Biocodex played a significant role in obtaining reimbursement for Circadin under a Temporary Recommendation for Use (RTU) for treating sleep disorders in children with neurodevelopmental disorders. It was only natural that the collaboration will deepen to include PedPRM," said Sharon Elkobi, VP Business Development of Neurim Pharmaceuticals. "Additional agreements are expected to follow in order to make the new treatment accessible for children and their families."

"Sleep disturbances in children presenting with neurodevelopment disabilities represent an unresolved therapeutic challenge. In addition to Circadin® for the treatment of primary insomnia in adults, Biocodex is pleased to expand its productive partnership with Neurim and is proud to continue the work being done on the RTU in order to make this new promising product available for these children in France," said Paul Bernasconi, MD, Vice President France Operations of Biocodex.

About PedPRM 

PedPRM is a response to an unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM has recently completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. The drug met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East.

The company has a strong and innovative product pipeline intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

Contact:
Sharon Elkobi
VP Business Development
sharone@neurim.com


'/>"/>
SOURCE Neurim Pharmaceuticals Ltd.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
4. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
5. Access Pharmaceuticals Reports First Quarter Results
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
9. Aveo Pharmaceuticals, Inc. Sued by Investor
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2018)... ... October 16, 2018 , ... SightMD (or the “Company”), a leading multi-specialty ophthalmology ... with Mid Island Eye Physicians & Surgeons (“Mid Island Eye” or “MIE”). The ... over 50 physicians and 25 convenient locations in New York. , For more ...
(Date:10/16/2018)... ... 16, 2018 , ... Cameras and monitoring are top-of-mind when people think about ... a key role in a family’s health and well-being. That’s why Home Expert ... a “Safe At Home” satellite media event today. , Lipford and Wolf connected ...
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... With suicide ... public health problem (1), the American Psychiatric Nurses Association (APNA) has released a new ... for suicide safe. Though deaths by suicide in hospital settings are preventable, a recent ...
Breaking Medicine Technology:
(Date:10/20/2018)... , ... October 19, 2018 , ... ... MRI and Ultrasound technologies earned him the Young Investigator Award for his abstract ... technique of protein engineering to the development of new imaging and therapeutic methods. ...
(Date:10/18/2018)... ... October 18, 2018 , ... Drummond Group, LLC, a ... Health Information Exchange Collaborative (SHIEC) as a Strategic Business and Technology (SB&T) Partner. ... Drummond Group is a HITRUST CSF Assessor that assists HIEs to become HITRUST ...
(Date:10/18/2018)... ... 2018 , ... Today Jon Elwell, CEO of Kno2 ®, the company ... National Association of Long Term Hospitals (NALTH) Fall Leadership Conference and Advocacy ... understanding that Waldo was in the picture somewhere. The challenge was finding him in ...
(Date:10/18/2018)... RIVER, N.Y. (PRWEB) , ... October 18, 2018 , ... ... today announced the names and qualifications of four doctors who have agreed to join ... strong addition to the brainpower and talent that is helping to guide Fellow Health ...
(Date:10/17/2018)... ... October 17, 2018 , ... Power to Decide, the ... Innovation Next program. Made possible with support from the HHS Office of ... health for the 21st century through a focus on technology-enabled ideas. , This year, ...
Breaking Medicine News(10 mins):